Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers

Heping Yan1, Vaishali Kapoor1, Kim Nguyen1

  • 1Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.

Oncotarget
|June 9, 2016
PubMed

Insights

A novel monoclonal antibody, 2C6F3, targets radiation-inducible neo-antigens like Tax interacting protein-1 (TIP-1) on cancer cells. Radio-immunoconjugates of 2C6F3 demonstrate specific tumor targeting and significantly inhibit tumor growth, offering a new cancer therapy approach.

Area of Science:

  • Oncology
  • Immunology
  • Radiochemistry

Background:

  • Radiation-inducible neo-antigens on cancer cells offer targeted therapy opportunities.
  • Tax interacting protein-1 (TIP-1) is a radiation-induced surface protein on cancer cells.

Purpose of the Study:

  • To develop and characterize a monoclonal antibody against TIP-1 for cancer targeting.
  • To evaluate the in vitro and in vivo efficacy of the anti-TIP-1 antibody and its radio-immunoconjugates.

Main Methods:

  • Developed monoclonal antibody 2C6F3 targeting the TIP-1 epitope QPVTAVVQRV.
  • Utilized Near-Infrared (NIR) and SPECT/CT imaging to assess in vivo tumor binding.
  • Conjugated 2C6F3 with chelators (DTPA) and radiolabeled with 111In and 90Y for imaging and therapy.

Main Results:

  • 2C6F3 specifically binds to TIP-1 on lung cancer and glioma cell lines.
  • In vivo studies confirmed specific binding of 2C6F3 to irradiated tumors.
  • 90Y-labeled 2C6F3 significantly delayed tumor growth in mice, demonstrating therapeutic potential.

Conclusions:

  • Monoclonal antibody 2C6F3 is a specific targeting agent for radiation-induced TIP-1 on cancer cells.
  • Radio-immunoconjugates of 2C6F3 show promise for targeted cancer imaging and therapy, improving tumor control.

Related Concept Videos